Founded in 2006, Longitude Capital invests in all stages of life sciences companies. However, the firm primary invests in early stage medical technology and mature biotechnology companies. Specifically, ventures should come up with (i) clinically effective solutions to address unmet medical needs, (ii) cost-effective treatment alternatives that reduce system-wide healthcare costs, and (iii) platform technologies that facilitate the development of novel products in life sciences.

Longitude seeks ventures with the following characteristics:

* Large target markets,
* Defensible and proprietary technology,
* High probabilities of product safety and efficacy,
* Defined reimbursement and commercial landscapes,
* Well defined, capital efficient business plans with identifiable value drivers, and
* Clear expectations for exit valuations.

Longitude invests between $10 million to $30 million over the life of each portfolio company, but initial investments can be much smaller, particularly in early stage opportunities. Longitude typically lead or co-lead their investments and request a seat on the board of directors.

Notable investments include: Allergen Research Corporation, California Cryobank, Cadence Pharmaceuticals (NASDAQ: CADX), Civitas Therapeutics (NASDAQ:CVTS, acquired by Acorda Therapeutics), Esperion Therapeutics (NASDAQ:ESPR), Solta Medical (NASDAQ: SLTM, acquired by Valeant Pharmaceuticals) and Venus Concept.